RU2009102262A - Композиции активного агента, способы их получения и способы применения - Google Patents
Композиции активного агента, способы их получения и способы применения Download PDFInfo
- Publication number
- RU2009102262A RU2009102262A RU2009102262/15A RU2009102262A RU2009102262A RU 2009102262 A RU2009102262 A RU 2009102262A RU 2009102262/15 A RU2009102262/15 A RU 2009102262/15A RU 2009102262 A RU2009102262 A RU 2009102262A RU 2009102262 A RU2009102262 A RU 2009102262A
- Authority
- RU
- Russia
- Prior art keywords
- active agent
- composition
- nanoparticles
- agent according
- less
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract 44
- 239000000203 mixture Substances 0.000 title claims abstract 28
- 239000002105 nanoparticle Substances 0.000 claims abstract 15
- 239000002245 particle Substances 0.000 claims abstract 10
- 239000003352 sequestering agent Substances 0.000 claims abstract 9
- 239000000725 suspension Substances 0.000 claims abstract 6
- 229920001577 copolymer Polymers 0.000 claims abstract 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract 4
- 238000005259 measurement Methods 0.000 claims abstract 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims abstract 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002297 fenofibrate Drugs 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims abstract 2
- 230000002209 hydrophobic effect Effects 0.000 claims abstract 2
- 150000003904 phospholipids Chemical class 0.000 claims abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract 2
- 229960002930 sirolimus Drugs 0.000 claims abstract 2
- 239000004094 surface-active agent Substances 0.000 claims abstract 2
- 229960001967 tacrolimus Drugs 0.000 claims abstract 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims abstract 2
- 229960003433 thalidomide Drugs 0.000 claims abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Композиция активного агента, содержащая ! наночастицы активного агента, имеющие эффективный средний размер частиц менее 2000 нм, и ! корпускулярный секвестрант, ! при этом композиция не содержит поверхностно-активных веществ или фосфолипидов, и ! при этом водная растворимость активного агента составляет менее 1 мг/мл. ! 2. Композиция активного агента по п.1, отличающаяся тем, что находится в форме суспензии. ! 3. Композиция активного агента по п.2, отличающаяся тем, что эффективный средний размер наночастиц в суспензии изменяется не более чем на 35% в течение 2 недель от первого измерения размера частиц. ! 4. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента и корпускулярный секвестрант расположены на ядре инертной частицы с образованием гранулята активного агента. ! 5. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента имеют D90 менее 1500 нм. ! 6. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента имеют D90 менее 1000 нм. ! 7. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента имеют D90 менее 500 нм. ! 8. Композиция активного агента по п.1, отличающаяся тем, что активный агент содержит фенофибрат, сиролимус, талидомид или такролимус. ! 9. Композиция активного агента по п.1, отличающаяся тем, что корпускулярный секвестрант содержит pH-чувствительный сополимер, имеющий как гидрофобные (мет)акрилатные звенья, так и кислоторастворимые (мет)акрилатные звенья. ! 10. Композиция активного агента по п.1, отличающаяся тем, что корпускулярный секвестрант содержит сополимер бутил метакрилат-(2-диметиламиноэт
Claims (15)
1. Композиция активного агента, содержащая
наночастицы активного агента, имеющие эффективный средний размер частиц менее 2000 нм, и
корпускулярный секвестрант,
при этом композиция не содержит поверхностно-активных веществ или фосфолипидов, и
при этом водная растворимость активного агента составляет менее 1 мг/мл.
2. Композиция активного агента по п.1, отличающаяся тем, что находится в форме суспензии.
3. Композиция активного агента по п.2, отличающаяся тем, что эффективный средний размер наночастиц в суспензии изменяется не более чем на 35% в течение 2 недель от первого измерения размера частиц.
4. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента и корпускулярный секвестрант расположены на ядре инертной частицы с образованием гранулята активного агента.
5. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента имеют D90 менее 1500 нм.
6. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента имеют D90 менее 1000 нм.
7. Композиция активного агента по п.1, отличающаяся тем, что наночастицы активного агента имеют D90 менее 500 нм.
8. Композиция активного агента по п.1, отличающаяся тем, что активный агент содержит фенофибрат, сиролимус, талидомид или такролимус.
9. Композиция активного агента по п.1, отличающаяся тем, что корпускулярный секвестрант содержит pH-чувствительный сополимер, имеющий как гидрофобные (мет)акрилатные звенья, так и кислоторастворимые (мет)акрилатные звенья.
10. Композиция активного агента по п.1, отличающаяся тем, что корпускулярный секвестрант содержит сополимер бутил метакрилат-(2-диметиламиноэтил) метакрилат-метил метакрилат.
11. Композиция активного агента по п.4, отличающаяся тем, что ядро инертной частицы имеет средний диаметр от 50 до 500 мкм.
12. Композиция активного агента по п.4, отличающаяся тем, что ядро инертной частицы содержит сахар, микрокристаллическую целлюлозу; фосфат кальция, лактозу, полимер, и сочетания, содержащие одно или несколько указанных выше ядер инертных частиц.
13. Композиция активного агента по п.1, отличающаяся тем, что находится в форме суспензии;
при этом корпускулярный секвестрант по существу состоит из сополимера бутил метакрилат-(2-диметиламиноэтил) метакрилат-метил метакрилат, и
при этом эффективный средний размер наночастиц в суспензии изменяется не более чем на 35% в течение 2 недель от первого измерения размера частиц.
14. Композиция активного агента по п.13, отличающаяся тем, что наночастицы активного агента имеют D90 менее 1000 нм.
15. Композиция активного агента по п.13, отличающаяся тем, что наночастицы активного агента имеют D90 менее 500 нм.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80582306P | 2006-06-26 | 2006-06-26 | |
| US60/805,823 | 2006-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009102262A true RU2009102262A (ru) | 2010-08-10 |
Family
ID=38704788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009102262/15A RU2009102262A (ru) | 2006-06-26 | 2007-06-26 | Композиции активного агента, способы их получения и способы применения |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20080050450A1 (ru) |
| EP (1) | EP2037888A2 (ru) |
| JP (1) | JP2009541485A (ru) |
| KR (1) | KR20090045205A (ru) |
| CN (1) | CN101505733A (ru) |
| AU (1) | AU2007265452A1 (ru) |
| BR (1) | BRPI0713533A2 (ru) |
| CA (1) | CA2656277A1 (ru) |
| CO (1) | CO6150124A2 (ru) |
| IL (1) | IL196108A0 (ru) |
| MX (1) | MX2009000035A (ru) |
| NO (1) | NO20090068L (ru) |
| RU (1) | RU2009102262A (ru) |
| WO (1) | WO2008002568A2 (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10100266B2 (en) | 2006-01-12 | 2018-10-16 | The Board Of Trustees Of The University Of Arkansas | Dielectric nanolubricant compositions |
| US8492319B2 (en) | 2006-01-12 | 2013-07-23 | Ajay P. Malshe | Nanoparticle compositions and methods for making and using the same |
| US20090074872A1 (en) * | 2006-06-26 | 2009-03-19 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
| US20080050450A1 (en) * | 2006-06-26 | 2008-02-28 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
| JP5704814B2 (ja) | 2006-10-19 | 2015-04-22 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | 静電噴霧を用いてコーティングを作る方法及び装置 |
| US10752997B2 (en) | 2006-10-19 | 2020-08-25 | P&S Global Holdings Llc | Methods and apparatus for making coatings using ultrasonic spray deposition |
| US9072664B2 (en) | 2008-05-22 | 2015-07-07 | 3M Innovative Properties Company | Process for manufacturing flowable powder drug compositions |
| US9956170B2 (en) | 2008-06-26 | 2018-05-01 | 3M Innovative Properties Company | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof |
| EP2309984B1 (en) | 2008-07-02 | 2018-04-11 | 3M Innovative Properties Company | Method of making a dry powder pharmaceutical composition |
| US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
| WO2010078429A1 (en) * | 2008-12-30 | 2010-07-08 | Impax Laboratories, Inc. | Pharmaceutical dosage forms and methods of manufacturing same |
| CA2759332A1 (en) * | 2009-04-21 | 2010-10-28 | Selecta Biosciences, Inc. | Immunonanotherapeutics providing a th1-biased response |
| CN106177940A (zh) | 2010-05-26 | 2016-12-07 | 西莱克塔生物科技公司 | 含有佐剂的合成纳米载体的剂量选择 |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| EA201390464A1 (ru) * | 2010-09-28 | 2013-08-30 | Рациофарм Гмбх | Способ сухой обработки атазанавира |
| US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| JP5824688B2 (ja) * | 2011-05-24 | 2015-11-25 | センカ株式会社 | ｐＨ応答性高分子微粒子及びその分散体の製造方法 |
| JP2015531749A (ja) * | 2012-06-21 | 2015-11-05 | メイン ファーマ インターナショナル プロプライエタリー リミテッドＭａｙｎｅ Ｐｈａｒｍａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｐｔｙ．Ｌｔｄ． | イトラコナゾール組成物及び投与剤形、並びにその使用方法 |
| US8486870B1 (en) | 2012-07-02 | 2013-07-16 | Ajay P. Malshe | Textured surfaces to enhance nano-lubrication |
| US8476206B1 (en) | 2012-07-02 | 2013-07-02 | Ajay P. Malshe | Nanoparticle macro-compositions |
| US9801820B2 (en) | 2012-11-12 | 2017-10-31 | New Jersey Institute Of Technology | Pharmaceutical core-shell composite powder and processes for making the same |
| MX2017000141A (es) * | 2014-07-03 | 2017-04-25 | Pfizer | Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. |
| CN110996907A (zh) | 2017-08-17 | 2020-04-10 | 豪夫迈·罗氏有限公司 | 用于碱性或中性低分子量化合物的新型药物组合物 |
| US20220175812A1 (en) | 2020-12-03 | 2022-06-09 | Battelle Memorial Institute | Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery |
| AU2022253899A1 (en) | 2021-04-07 | 2023-10-26 | Battelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2586597A (en) * | 1948-06-17 | 1952-02-19 | Bell Telephone Labor Inc | Oscillation generator |
| US2841138A (en) * | 1957-03-11 | 1958-07-01 | Ernest S V Laub | Allergy testing device |
| US4058552A (en) * | 1969-01-31 | 1977-11-15 | Orchimed Sa | Esters of p-carbonylphenoxy-isobutyric acids |
| FR2602423B1 (fr) * | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
| FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| DE4228156C1 (de) * | 1992-08-25 | 1993-10-21 | Daimler Benz Ag | Kraftstoffilteranordnung für eine Brennkraftmaschine |
| US5346702A (en) * | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| DE4329446A1 (de) * | 1993-09-01 | 1995-03-02 | Basf Ag | Verfahren zur Herstellung von feinteiligen Farb- oder Wirkstoffzubereitungen |
| TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| FR2721510B1 (fr) * | 1994-06-22 | 1996-07-26 | Rhone Poulenc Rorer Sa | Nanoparticules filtrables dans des conditions stériles. |
| US5587143A (en) * | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560932A (en) * | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5716642A (en) * | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
| US5569448A (en) * | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5571536A (en) * | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5622938A (en) * | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5534270A (en) * | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US6391338B1 (en) * | 1995-09-07 | 2002-05-21 | Biovail Technologies Ltd. | System for rendering substantially non-dissoluble bio-affecting agents bio-available |
| FR2742357B1 (fr) * | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | Nanoparticules stabilisees et filtrables dans des conditions steriles |
| US6649192B2 (en) * | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
| US6153525A (en) * | 1997-03-13 | 2000-11-28 | Alliedsignal Inc. | Methods for chemical mechanical polish of organic polymer dielectric films |
| US6726934B1 (en) * | 1997-10-09 | 2004-04-27 | Vanderbilt University | Micro-particulate and nano-particulate polymeric delivery system |
| FR2775435B1 (fr) * | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| KR100622047B1 (ko) * | 1998-06-19 | 2006-09-07 | 스키에파마 캐나다 인코포레이티드 | 수-불용성 화합물의 서브마이크론 입자의 제조방법 |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US7939105B2 (en) * | 1998-11-20 | 2011-05-10 | Jagotec Ag | Process for preparing a rapidly dispersing solid drug dosage form |
| US6180138B1 (en) * | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| CA2270306C (en) * | 1999-04-27 | 2000-09-26 | Bernard Charles Sherman | Pharmaceutical compositions comprising co-micronized fenofibrate |
| US6368620B2 (en) * | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
| US7863331B2 (en) * | 1999-07-09 | 2011-01-04 | Ethypharm | Pharmaceutical composition containing fenofibrate and method for the preparation thereof |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CA2396380C (en) * | 1999-12-23 | 2015-04-21 | David Hayes | Improved pharmaceutical compositions for poorly soluble drugs |
| US6482439B2 (en) * | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| US7153525B1 (en) * | 2000-03-22 | 2006-12-26 | The University Of Kentucky Research Foundation | Microemulsions as precursors to solid nanoparticles |
| US6316029B1 (en) * | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| CA2415643C (en) * | 2000-07-17 | 2010-11-16 | Yamanouchi Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral use with improved absorption |
| US6531158B1 (en) * | 2000-08-09 | 2003-03-11 | Impax Laboratories, Inc. | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients |
| EP1322289B1 (en) * | 2000-09-20 | 2007-07-25 | Jagotec AG | Spray drying process of compositions containing fenofibrate |
| US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
| US7094810B2 (en) * | 2001-06-08 | 2006-08-22 | Labopharm, Inc. | pH-sensitive block copolymers for pharmaceutical compositions |
| GB0119480D0 (en) * | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| US7037900B2 (en) * | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
| EP1467709A1 (en) * | 2002-01-14 | 2004-10-20 | Dow Global Technologies Inc. | Drug nanoparticles from template emulsions |
| AU2003225285A1 (en) * | 2002-05-03 | 2003-11-17 | Skyepharma Canada Inc. | Oral dosage forms comprising fenofibrate |
| FR2841138B1 (fr) * | 2002-06-25 | 2005-02-25 | Cll Pharma | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
| US20040220081A1 (en) * | 2002-10-30 | 2004-11-04 | Spherics, Inc. | Nanoparticulate bioactive agents |
| JP2006507309A (ja) * | 2002-10-31 | 2006-03-02 | アルザ・コーポレーシヨン | 疎水性薬剤の上昇した生物学的利用性を提供する製剤 |
| FR2855756B1 (fr) * | 2003-06-06 | 2005-08-26 | Ethypharm Sa | Comprime orodispersible multicouche |
| US8062664B2 (en) * | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
| US7282194B2 (en) * | 2004-10-05 | 2007-10-16 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| EP1827416A1 (en) * | 2004-12-03 | 2007-09-05 | Abbott Laboratories | Pharmaceutical compositions |
| DE102004059792A1 (de) * | 2004-12-10 | 2006-06-14 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| WO2007070082A1 (en) * | 2005-05-10 | 2007-06-21 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising teprenone |
| US8231907B2 (en) * | 2006-03-21 | 2012-07-31 | Morehouse School Of Medicine | Nanoparticles for delivery of active agents |
| US20080050450A1 (en) * | 2006-06-26 | 2008-02-28 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
| US20090074872A1 (en) * | 2006-06-26 | 2009-03-19 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
-
2007
- 2007-06-26 US US11/768,476 patent/US20080050450A1/en not_active Abandoned
- 2007-06-26 CN CNA2007800266959A patent/CN101505733A/zh active Pending
- 2007-06-26 EP EP07809903A patent/EP2037888A2/en not_active Withdrawn
- 2007-06-26 WO PCT/US2007/014818 patent/WO2008002568A2/en not_active Ceased
- 2007-06-26 JP JP2009518224A patent/JP2009541485A/ja active Pending
- 2007-06-26 KR KR1020097001730A patent/KR20090045205A/ko not_active Withdrawn
- 2007-06-26 BR BRPI0713533-5A patent/BRPI0713533A2/pt not_active IP Right Cessation
- 2007-06-26 RU RU2009102262/15A patent/RU2009102262A/ru not_active Application Discontinuation
- 2007-06-26 CA CA002656277A patent/CA2656277A1/en not_active Abandoned
- 2007-06-26 AU AU2007265452A patent/AU2007265452A1/en not_active Abandoned
- 2007-06-26 MX MX2009000035A patent/MX2009000035A/es not_active Application Discontinuation
-
2008
- 2008-05-16 US US12/122,402 patent/US20080220076A1/en not_active Abandoned
- 2008-12-22 IL IL196108A patent/IL196108A0/en unknown
-
2009
- 2009-01-06 CO CO09000700A patent/CO6150124A2/es unknown
- 2009-01-06 NO NO20090068A patent/NO20090068L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL196108A0 (en) | 2009-09-01 |
| WO2008002568A3 (en) | 2008-04-17 |
| AU2007265452A1 (en) | 2008-01-03 |
| MX2009000035A (es) | 2009-05-28 |
| US20080220076A1 (en) | 2008-09-11 |
| US20080050450A1 (en) | 2008-02-28 |
| WO2008002568A2 (en) | 2008-01-03 |
| CN101505733A (zh) | 2009-08-12 |
| CO6150124A2 (es) | 2010-04-20 |
| KR20090045205A (ko) | 2009-05-07 |
| BRPI0713533A2 (pt) | 2012-04-17 |
| EP2037888A2 (en) | 2009-03-25 |
| AU2007265452A2 (en) | 2009-04-23 |
| NO20090068L (no) | 2009-03-23 |
| CA2656277A1 (en) | 2008-01-03 |
| JP2009541485A (ja) | 2009-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009102262A (ru) | Композиции активного агента, способы их получения и способы применения | |
| Judy et al. | Effects of silver sulfide nanomaterials on mycorrhizal colonization of tomato plants and soil microbial communities in biosolid-amended soil | |
| Huo et al. | Osteogenic activity and antibacterial effects on titanium surfaces modified with Zn-incorporated nanotube arrays | |
| Sendra et al. | CeO2 NPs, toxic or protective to phytoplankton? Charge of nanoparticles and cell wall as factors which cause changes in cell complexity | |
| RU2009109353A (ru) | Композиции на основе наночастиц | |
| Krishnaraj et al. | In vitro antiplatelet activity of silver nanoparticles synthesized using the microorganism Gluconobacter roseus: an AFM-based study | |
| ATE492301T1 (de) | Absorbierende artikel enthaltend beschichtete superabsorbierende partikel | |
| WO2007006353A3 (de) | Verwendung eines teilneutralisierten, anionischen (meth) acrylat-copolymers als uberzug fur die herstellung einer arzneiform mit einer wirkstofffreisetzung bei erniedrigten ph-werten | |
| DK1663217T3 (da) | Faste dispersioner indeholdende tacrolimus | |
| Balaure et al. | Fabrication, characterization and in vitro profile based interaction with eukaryotic and prokaryotic cells of alginate–chitosan–silica biocomposite | |
| FR2755612A1 (fr) | Composition superabsorbante pour articles d'hygiene ne developpant pas d'odeurs incommodantes | |
| WO2008054205A3 (en) | Homogeneous, intrinsic radiopaque embolic particles | |
| WO2007141344A3 (fr) | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques | |
| US11358879B2 (en) | Excrement treatment agent | |
| CY1112917T1 (el) | Υγρες στοματικες συνθεσεις | |
| Rasool et al. | Development of coated beads for oral controlled delivery of cefaclor: In vitro evaluation | |
| CN105964230B (zh) | 一种锆改性复合吸附剂及其制备方法和应用 | |
| AR057212A1 (es) | Composicion de liberacion prolongada del principio activo, su proceso de preparacion y su utilizacion | |
| IL274149B1 (en) | Extended release formulations for intra-articular applications | |
| CN106345427A (zh) | 一种球形脱汞吸附剂的制备方法与产品及其应用 | |
| Kitchin et al. | Biochemical effects of six TiO2 and four CeO2 nanomaterials in HepG2 cells | |
| CN104666342A (zh) | 可降低体内尿毒素的吸附剂 | |
| CN112624249B (zh) | 一种用于污水处理的复合材料 | |
| Dwivedi et al. | Overwhelming antibacterial activity by Terminalia arjuna aided herbal Ag/CS-PVC: nanocomposite for overcoming biomaterials associated infections | |
| Supriadi et al. | Calcium Carbonate from Eggshell Nanosuspension preparation by Bead Mill Method and its Antacid and Antibacterial activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100628 |